From GlobeNewswire: 2025-04-29 08:05:00

LifeMD, Inc. announces plans to offer streamlined access to Wegovy® through NovoCare® Pharmacy for cash-pay patients, providing a simplified pathway to FDA-approved dose strengths of the medication within LifeMD’s virtual care platform. The integration enhances LifeMD’s weight management program, offering brand-name GLP-1 therapy at a reduced self-pay cost of $499 per month, including home delivery. This initiative reflects the increasing demand for convenient access to clinically backed FDA-approved obesity treatment options, with all doses of Wegovy® available in a pen device to eligible LifeMD patients. Wegovy® is the first GLP-1 therapy approved in the U.S. for chronic weight management and cardiovascular risk reduction. LifeMD, Inc. is a leading provider of virtual primary care, offering telemedicine, laboratory and pharmacy services, and specialized treatment across over 200 conditions. The company aims to increase access to high-quality and affordable care through its integrated digital care platform, affiliated medical group, pharmacy, and patient care center.



Read more at GlobeNewswire: LifeMD Announces Plans to Expand Affordable Access to